Back to News & Events

Ohr Pharmaceutical & Cold Spring Harbor Laboratory Announce Joint Venture

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, and Cold Spring Harbor Laboratory (CSHL) have announced the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs.

The new joint venture will be a private entity, initially with equal ownership by Ohr and Cold Spring Harbor Laboratory. The two partners will seek funding and contribute to the research and development of trodusquemine and also newly patented analogs. The goal is to take the program into the clinic and to demonstrate proof of concept.

Andreas Grill, former Executive Director of Forest Research Institute for Forest Laboratories, Inc and current Center for Biotechnology BioEntrepreneur-inResidence has been tapped to serve as Chief Executive Office for DepYmed.

Read the full press release here.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4488
                    [post_author] => 4
                    [post_date] => 2024-10-24 10:45:00
                    [post_date_gmt] => 2024-10-24 14:45:00
                    [post_content] => 

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2025-02-26 16:35:20 [post_modified_gmt] => 2025-02-26 21:35:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3396 [post_author] => 3 [post_date] => 2019-12-06 19:14:13 [post_date_gmt] => 2019-12-06 19:14:13 [post_content] => The Federal SBIR/STTR programs award over $3 billion in high risk R&D funding annually to qualified small businesses. The process is complex but the impact of receiving millions in non-dilutive funding is worth the effort. On January 15-16, 2020, the Center for Biotechnology will be hosting a intensive, 1.5 day workshop led by  well-known program expert and trainer, Becky Aistrup, M.B.A., Managing Partner of BBC Entrepreneurial Training & Consulting LLC. This 1.5-day session focused on the National Institutes of Health (NIH) will cover program essentials and how to compete for funding. Training is open to the public and will include:
  • Current information on the SBIR/STTR programs
  • Strategies for targeting your proposal to address the mission and requirements of the NIH
  • How to approach each section of your proposal
  • Planning your commercialization strategy
  • Writing to meet the reviewers’ expectations
Dates & Times Wed, Jan 15, 2020, 8:30 AM – 4:30 PM Thu, Jan 16, 2020 8:30 AM –12:00 PM EST Location Long Island High Technology Incubator Main Conference Room 25 Health Sciences Drive Stony Brook, NY 11794 Registration Fee: $60 Space is Limited. Pre-registration is required. REGISTER ONLINE Interested participants have the opportunity to apply for partial-sponsored follow on counseling via one-on-one proposal mentoring with SBIR/STTR experts. More info here. PLEASE NOTE: This training is mandatory for those who will be submitting applications for the One-on-One proposal counseling. [post_title] => Proposal Development Workshop: SBIR/STTR for NIH [post_excerpt] => The Federal SBIR/STTR programs award over $3 billion in high risk R&D funding annually to qualified small businesses. Learn if this opportunity is right for your technology how to develop a competitive proposal at our annual workshop. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => proposal-development-workshop-sbirsttr-for-nih [to_ping] => [pinged] => [post_modified] => 2019-12-06 19:14:13 [post_modified_gmt] => 2019-12-06 19:14:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3396 [menu_order] => 82 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 4415 [post_author] => 4 [post_date] => 2024-05-12 10:36:49 [post_date_gmt] => 2024-05-12 14:36:49 [post_content] =>

Governor Hochul has launched ESD’s $6 million Innovation Matching Grants Program, which was first proposed in her 2023 State of the State address. This program provides application support and technical assistance to New York companies applying for the federal Small Business Innovation Research and Small Business Technology Transfer grant programs, which incentivize small businesses to engage in research and development with the potential for commercialization.

Under the program, ESD will match up to $100,000 for a successful concept development, or Phase I award, and up to $200,000 for a prototype development, or Phase II award. The Division will also provide technical assistance resources for Phase II and Phase III awardees. Applications and guidelines can be found here: https://esd.ny.gov/innovation-matching-grants-program

[post_title] => NY Governor Launches $6 Million Innovation Matching Grant Program to Support Small Businesses Participating in SBIR/STTR Programs  [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ny-governor-launches-6-million-innovation-matching-grant-program-to-support-small-businesses-participating-in-sbir-sttr-programs [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:47:18 [post_modified_gmt] => 2024-11-19 15:47:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4415 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2563 [post_author] => 3 [post_date] => 2017-01-12 19:50:10 [post_date_gmt] => 2017-01-12 19:50:10 [post_content] => New York City based start-up Celmatix has unveiled “Fertilome”, a DNA-based fertility test. The company describes Fertilome as the “first genetic screen that examines a woman’s genetic signature and how it may impact her reproductive health and ability to conceive, today and in the future.” Fertilome looks at 49 variants in 32 genes associated with a broad spectrum of female reproductive conditions. Information derived from the test could allow women to see a broader picture of their fertility, allowing for a more proactive approach to planning their family and overcoming fertility issues. Click here to read more about Celmatix and Fertilome. [post_title] => Celmatix unveils Fertilome [post_excerpt] => New York City based start-up Celmatix has unveiled “Fertilome”, a DNA-based fertility test. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => celmatix-unveils-fertilome [to_ping] => [pinged] => [post_modified] => 2017-02-28 14:29:44 [post_modified_gmt] => 2017-02-28 14:29:44 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2563 [menu_order] => 154 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4488 [post_author] => 4 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 [post_content] =>

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2025-02-26 16:35:20 [post_modified_gmt] => 2025-02-26 21:35:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 270 [max_num_pages] => 90 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

More Information

Proposal Development Workshop: SBIR/STTR for NIH

More Information

NY Governor Launches $6 Million Innovation Matching Grant Program to Support Small Businesses Participating in SBIR/STTR Programs 

More Information

Celmatix unveils Fertilome

More Information